Welcome, Guest

Donald Durden, MD

Donald Durden, MD

Donald Durden, MD, PhD, Vice Chair for Research of the Department of Pediatrics at the University of California, San Diego (UCSD) and Associate Director for Pediatric Oncology at the Moores UCSD Cancer Center, discusses how multi-omics will advance cancer research and improve treatments.

While technological breakthroughs of the last decade have greatly advanced our understanding of the cancer genome, they have also revealed that not all DNA-level alterations have biological implications. This, in turn, makes it necessary to examine multiple omic levels to identify the entire spectrum of alterations in a tumor and to figure out how to treat it.

Dr. Durden, a pediatric oncologist and translational cancer researcher, recognizes the importance of taking a multi-omics approach to both his basic research and to the design of his clinical trials. He recently sat down with Affymetrix to discuss the benefits, challenges, and potential impact of using multi-omic analyses for cancer research and treatment.

Why would I take a DNA sample from a tumor and expect that alone is going to tell me the answer?
Read the full article. Download the pdf version to enjoy the article in its entirety and also keep it for future reference. Avaliable in PDF (1.5 MB)

More Scientist Spotlights

  • Mady Hornig, MD Mady Hornig, MA, MD, Director of Translational Medicine at Columbia University, discusses the use multiplexed immunoassays for studying chronic fatigue syndrome, known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
  • Jizeng Jia, PhD Jizeng Jia, PhD, from the Institute of Crop Sciences, Chinese Academy of Agriculture Science, Beijing, discusses the limitations of current technologies and how they were overcome to develop the highest density wheat array commercially available.
  • Gordon Mills, MD Gordon Mills, MD, PhD, of the University of Texas MD Anderson Cancer Center and "Dream Team" co-leader in Stand Up To Cancer®, discusses the importance of genomic profiling in the discovery of novel predictive markers to improve the effectiveness of cancer treatment.
  • Mark I. McCarthy, MD Professor Mark McCarthy, from the University of Oxford, UK, outlines how the intersection of biobank capabilities, new study designs, and technological advances will improve our understanding of complex trait genetics.
  • Bruno Stuhlmüller, PhD Bruno Stuhlmüller, PhD, head of the scientific laboratory and team leader at the Institute of the Rheumatology and Clinical Immunology department at the Charité Free University and Humboldt University, Berlin, discusses working with whole blood samples to identify mRNA and miRNA biomarkers for predictive rheumatoid arthritis treatments.
  • Peter Ambros, PhD Peter Ambros, PhD, Associate Professor at the Children's Cancer Research Institute (CCRI) in Vienna, Austria discusses the way in which arrays are helping to unravel the complexities of the cancer genome and guiding patient-tailored treatment strategies.
  • Austin Tanney, PhD Austin Tanney, PhD, Scientific Liaison Manager for Almac Diagnostics, UK, discusses the opportunities and challenges of working with FFPE tissue, and his visions for technologies driving towards personalized medicine.
  • Jay Tiesman, PhD Procter & Gamble Company's Jay Tiesman, PhD, discusses the role of genomics in the cosmetics industry.
  • Joshua Schiffman, MD The University of Utah's Joshua Schiffman, MD, discusses the use of molecular inversion probe (MIP) technology for studying copy number alterations in pediatric cancers.
  • Lisa Baumbach, MD The University of Miami's Lisa Baumbach and Maastricht University's Torik Ayoubi discuss how ethnicity-specific genetic changes govern aggressive breast cancer risks.
  • Chris Smith, PhD Chris Smith of Cambridge University, Tyson Clark of Affymetrix and Melissa Cline of UCSC discuss EURASNET's approach for comparing commercial microarrays.
  • Robert Norgren, PhD Rob Norgren of The University of Nebraska Medical Center and Katja Nowick of Lawrence Livermore National Laboratory discuss the development of the Rhesus Macaque Genome Array.
  • Yong-Jie Lu, PhD Yong-Jie Lu of Queen Mary, University of London and Colleen Elso of the Walter and Eliza Hall Institute discuss a method for rapidly identifying chromosome rearrangements.

Scientist Spotlights

  • Scientist Spotlight (pdf, 1.5 MB) The development of a powerful tool for evaluating genetic diversity and investigating the genetic basis of trait variations in polyploid wheat

Archived Webinars

Warning! The earliest signals for cancer – miRNA regulation

Donald Durden, MD | Researchers | Community